Orexin-Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine [PDF]
, 2015 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced cocaine-seeking behavior.
Aguinaga, David +17 more
core +1 more source
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
Parkinson's Disease, 2012 In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias.
Nicola Tambasco +7 more
doaj +1 more source
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. [PDF]
, 2013 RationaleImpaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive
Acheson, Dean T +2 more
core +2 more sources
Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome:therapeutic perspectives for 5-HT1A agonists [PDF]
, 2014 Rett syndrome is a neurological disorder caused by loss of function of methyl-CpG-binding protein 2 (MeCP2). Reduced function of this ubiquitous transcriptional regulator has a devastating effect on the central nervous system.
Abdala, Ana Paula +2 more
core +2 more sources
Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
Journal of Investigative Medicine High Impact Case Reports, 2021 Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine.
Lakshmi P. Menon MD, Wedad Rahman MD
doaj +1 more source
Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. [PDF]
, 2017 BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD).
de Boer, L +6 more
core +2 more sources
Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels [PDF]
, 2013 Objective Impulse control disorders are commonly associated with dopaminergic therapy in Parkinson's disease (PD). PD patients with impulse control disorders demonstrate enhanced dopamine release to conditioned cues and a gambling task on [11C]raclopride
A. Rizos +43 more
core +1 more source
Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease
Clinical Parkinsonism & Related Disorders, 2021 Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall +5 more
doaj
Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
Frontiers in Pharmacology, 2020 Dopamine receptors are widely distributed within the brain where they play critical modulator roles on motor functions, motivation and drive, as well as cognition.
Jean Claude Martel +1 more
doaj +1 more source
Conditioned place preference and locomotor activity in response to methylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors [PDF]
, 2010 Methylphenidate (MP) and amphetamine (AMPH) are the most frequently prescribed medications for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Bermeo, C. +6 more
core +1 more source